Clinical trialNCT02862275Active, not recruitingPhase 1Interventional

Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer

SponsorNational Cancer Institute (NCI)Enrollment40Hematopoietic and Lymphoid Cell NeoplasmMetastatic Malignant Solid NeoplasmUnresectable Malignant Solid Neoplasm

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This pilot phase I trial studies the side effects of atezolizumab in treating patients with cancer following adoptive cell transfer. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Marcus O Butler
University Health Network Princess Margaret Cancer Center LAO
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada

University Health Network-Princess Margaret Hospital
Toronto, Ontario, Canada

United States

Uc San Diego Moores Cancer Center
La Jolla, California, United States
Moffitt Cancer Center
Tampa, Florida, United States
Moffitt Cancer Center-International Plaza
Tampa, Florida, United States
Emory Saint Joseph'S Hospital
Atlanta, Georgia, United States
Emory University Hospital Midtown
Atlanta, Georgia, United States
Emory University Hospital/winship Cancer Institute
Atlanta, Georgia, United States
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
Ut Md Anderson Cancer Center
Houston, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Atezolizumab →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 24 May 2017
Primary completion: 21 Nov 2026
Completion: 21 Nov 2026
Last update posted: 17 Jun 2026
Registered enrollment: 40
Registry id: NCT02862275

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.